Percheron Therapeutics (ASX:PER) has bolstered its executive ranks with the appointment of two seasoned biotechnology leaders as the company prepares to advance its lead oncology program, HMBD-002, into the next phase of development. …
Percheron strengthens leadership team ahead of next trial for HMBD-002
September 23, 2025 Australian Biotech
Latest Video
New Stories
-
Todd Stephenson confirmed on ACT list for New Zealand election
September 14, 2026 - - Latest News -
Scandal-hit KPMG still holds $37 million in health department work
September 14, 2026 - - Latest News -
Canberra details tax changes with limited concessions for some innovators
September 14, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 11 September
September 11, 2026 - - Podcast -
Rare genetic motor neurone disease treatment finally reaches Australian patients
September 11, 2026 - - Latest News -
NSW pharmacists to deliver all childhood vaccines and treat more conditions under reforms
September 11, 2026 - - Latest News -
AI Health Summit 2026
September 10, 2026 - - Summit